Insupport of the importance of IFNy gene signature, Johnson and colleagues [35] showed that high MHC class II (HLA-DR)expression was associated with improved clinical response, longer progression-freesurvival, and longer overall survival in patients with melanoma given anti-PD-1 oranti-PD-L1 therapy. Here, PDCD1 is linked to melanoma.